Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price & Analysis
Alnylam Pharmaceuticals, Inc. (ALNY) is trading at USD 223.24, down 1.78% today, as of October 23, 2026 at 15:07 UTC (US market open; quotes may be delayed), according to Nexqual market data.
ALNY last closed at USD 227.28; today's session has ranged USD 222–227.28 on volume of 239,900 shares. Market capitalization is $29.87B, with a 52-week range of USD 197.81–485.36 (NMS). Source: Nexqual, retrieved October 23, 2026 at 15:07 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ALNY.md
Key facts (ALNY)
- Valuation: P/E 40.7x (avg 170.7x at the last 1 fiscal year-ends), net cash $2.30B.
- 1 of 80 tracked superinvestors hold ALNY (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 3 Form 4 filings, $2.8M; 1 not under a Rule 10b5-1 plan ($399K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.03 on a 1–5 scale) (30 analysts), mean target USD 368.7 (range 250–536).
- Total return with dividends: 1Y -51.9% vs S&P 500 +14.8%; 5Y +39.9% vs S&P 500 +77.5%.
- Next earnings: 2026-10-29, EPS estimate USD 2.25, revenue estimate $1.43B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ALNY)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $844M | $1.04B | $1.83B | $2.25B | $3.71B | — |
| Gross profit | $729M | $897M | $1.56B | $1.94B | $3.04B | — |
| Operating income | -$709M | -$785M | -$282M | -$177M | $502M | — |
| Net income | -$853M | -$1.13B | -$440M | -$278M | $314M | $733M |
| EPS (diluted) | -$7.20 | -$9.30 | -$3.52 | -$2.18 | $2.33 | — |
| Free cash flow | -$718M | -$613M | $41.9M | -$42.6M | $465M | — |
| Gross margin | 86.4% | 86.5% | 85.3% | 86.4% | 81.8% | — |
| Operating margin | -83.9% | -75.7% | -15.4% | -7.9% | 13.5% | — |
| Net margin | -101.0% | -109.0% | -24.1% | -12.4% | 8.4% | — |
| Revenue growth | +71.3% | +22.9% | +76.2% | +23.0% | +65.2% | — |
| Cash + short-term investments | $2.37B | $2.16B | $2.43B | $2.69B | $2.91B | — |
| Total debt | $676M | $1.02B | $1.02B | $1.02B | $1.01B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ALNY)
P/E 40.7x · P/B 22.1x · Earnings yield 2.45% · Net cash $2.30B · EV $27.6B
P/E at fiscal year-ends: Dec 2025 170.7x.
Superinvestors (SEC 13F-HR, Q2 2026) (ALNY)
1 of 80 tracked investors hold ALNY. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Dodge & Cox Funds | Dodge & Cox | 0.31% | $589M | Added +1.4% |
Insider sales (SEC Form 4, open-market, last ~7 months) (ALNY)
2 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Supran Bryan | EVP, CLO and Secretary | 1,758 | $399K | 12.1% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-06-01 | Pyott David E I | Director | 3,830 | $1.1M | 11.5% | Yes (adopted November 12, 2025) | Too little history (no open-market trades in 2023) |
| 2026-04-02…2026-04-06 | McLaughlin Melissa | Chief Human Resources Officer | 3,910 | $1.3M | 29.3% | Yes (adopted December 16, 2025) | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (ALNY)
Consensus Buy (mean 2.03 on a 1–5 scale), 30 analysts; mean target USD 368.7 (low 250, high 536).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Citigroup | Target lowered | Buy | $340 → $320 |
| 2026-10-14 | Wells Fargo | Target lowered | Equal-Weight | $256 → $253 |
| 2026-10-08 | RBC Capital | Target lowered | Outperform | $350 → $345 |
| 2026-09-30 | JP Morgan | Target lowered | Overweight | $375 → $369 |
| 2026-09-21 | HC Wainwright & Co. | Reiterated | Buy | $455 |
| 2026-09-08 | Jefferies | Target raised | Hold | $230 → $260 |
| 2026-09-02 | HC Wainwright & Co. | Reiterated | Buy | $455 |
| 2026-08-19 | BMO Capital | Initiated | Outperform | $318 |
| 2026-08-14 | Wells Fargo | Target lowered | Equal-Weight | $316 → $256 |
| 2026-08-04 | Truist Securities | Target lowered | Buy | $410 → $315 |
| 2026-08-04 | HC Wainwright & Co. | Target lowered | Buy | $485 → $455 |
| 2026-08-03 | Raymond James | Upgrade | Outperform → Strong Buy | $420 |
Total return (dividends reinvested) (ALNY)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -51.9% | +39.9% |
| S&P 500 (SPY) | +14.8% | +77.5% |
| Per year | -51.9% | +7.0% |
| Volatility (annualized) | 51.4% | 49.4% |
| Max drawdown | -57.3% (Oct 2025→Jul 2026) | -57.3% (Oct 2025→Jul 2026) |
ALNY revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Net product revenues | $1.17B | 90.8% | +74.4% |
| — AMVUTTRA (part of Net product revenues) | $1.01B | 78.4% | +105.7% |
| — GIVLAARI (part of Net product revenues) | $89.8M | 7.0% | +11.0% |
| — Royalty revenue (part of Net product revenues) | $71.7M | 5.6% | +79.3% |
| Total TTR | $1.03B | 79.8% | +89.2% |
| Total Rare | $141.9M | 11.0% | +11.1% |
| OXLUMO | $52.1M | 4.0% | +11.2% |
| Net revenues from collaborations | $47.2M | 3.7% | -23.3% |
| ONPATTRO | $18.5M | 1.4% | -64.9% |
| Total revenue | $1.29B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
ALNY suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | AGILENT TECHNOLOGIES, INC. (A) | “In 2020, we amended our commercial supply agreement with Agilent to provide for Agilent to supply, subject to any conflicting obligations under our third-party agreements, a specified percentage of the API for certain of our commercial products.” |
| Partner | REGENERON PHARMACEUTICALS, INC. (REGN) | “Our collaborator, Regeneron Pharmaceuticals, Inc., or Regeneron, is advancing cemdisiran in combination with its anti-C5 monoclonal antibody, pozelimab, in a Phase 3 clinical trial” |
| Partner | NOVARTIS AG (NVS) | “Leqvio (inclisiran) is being developed and commercialized by our collaborator Novartis AG, or Novartis, and has received marketing authorization from the European Commission, or EC, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia and from the FDA as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia, or H…” |
| Partner | Sanofi (SNY) | “Qfitlia (fitusiran) is being commercialized by our collaborator, Genzyme Corporation, a Sanofi Company, or Sanofi, and was approved by the FDA in March 2025 for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B, with or without factor VIII or IX inhibitors (neutralizing antibodies), and by China's National Me…” |
| Partner | Vir Biotechnology, Inc. (VIR) | “Elebsiran (formerly ALN-HBV02 (VIR-2218)) is a subcutaneously administered, investigational RNAi therapeutic targeting the HBV genome for the treatment of chronic hepatitis delta, or CHD, which is being advanced by our collaborator, Vir Biotechnology, Inc., or Vir.” |
| Partner | IONIS PHARMACEUTICALS INC (IONS) | “Ionis Pharmaceuticals, Inc. In January 2015, we and Ionis Pharmaceuticals, Inc., or Ionis, entered into a second amended and restated strategic collaboration and license agreement, which we further amended in July 2015, or the 2015 Ionis agreement.” |
| Partner | PeptiDream | “In addition, we are exploring peptide and antibody-based approaches for targeted siRNA delivery to new tissues, including as part of our collaboration with PeptiDream, Inc., which aims to discover and develop novel conjugates for targeted delivery of RNAi therapeutics to a broader range of tissues.” |
| Partner | ADARx Pharmaceuticals, Inc. (ADRX) | “Companies working on chemically synthesized siRNAs include but are not limited to ADARx Pharmaceuticals, Inc., or ADARx, Amgen Inc., Argo Biopharmaceutical Co., Ltd., or Argo, Aro Biotherapeutics, Arrowhead Pharmaceuticals, Inc., or Arrowhead, AstraZeneca plc, or AstraZeneca, Dyne Therapeutics, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Novartis, Novo Nordisk A/S, or Novo Nordisk, SanegeneBio, Sarepta Thera…” |
| Partner | Novo Nordisk (NVO) | “Companies working on chemically synthesized siRNAs include but are not limited to ADARx Pharmaceuticals, Inc., or ADARx, Amgen Inc., Argo Biopharmaceutical Co., Ltd., or Argo, Aro Biotherapeutics, Arrowhead Pharmaceuticals, Inc., or Arrowhead, AstraZeneca plc, or AstraZeneca, Dyne Therapeutics, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Novartis, Novo Nordisk A/S, or Novo Nordisk, SanegeneBio, Sarepta Thera…” |
| Partner | Hoffmann-La Roche | “Hoffmann-La Roche Ltd. and Genentech, Inc. or, collectively, Roche, pursuant to which we established a worldwide, strategic collaboration for the joint development and commercialization of zilebesiran.” |
| Partner | Genentech | “Hoffmann-La Roche Ltd. and Genentech, Inc. or, collectively, Roche, pursuant to which we established a worldwide, strategic collaboration for the joint development and commercialization of zilebesiran.” |
| Partner | AMGEN INC (AMGN) | “Companies working on chemically synthesized siRNAs include but are not limited to ADARx Pharmaceuticals, Inc., or ADARx, Amgen Inc., Argo Biopharmaceutical Co., Ltd., or Argo, Aro Biotherapeutics, Arrowhead Pharmaceuticals, Inc., or Arrowhead, AstraZeneca plc, or AstraZeneca, Dyne Therapeutics, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Novartis, Novo Nordisk A/S, or Novo Nordisk, SanegeneBio, Sarepta Thera…” |
| Partner | Argo Biopharmaceutical | “Companies working on chemically synthesized siRNAs include but are not limited to ADARx Pharmaceuticals, Inc., or ADARx, Amgen Inc., Argo Biopharmaceutical Co., Ltd., or Argo, Aro Biotherapeutics, Arrowhead Pharmaceuticals, Inc., or Arrowhead, AstraZeneca plc, or AstraZeneca, Dyne Therapeutics, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Novartis, Novo Nordisk A/S, or Novo Nordisk, SanegeneBio, Sarepta Thera…” |
| Competitor | Pfizer (PFE) | “For example, AMVUTTRA is administered through a subcutaneous injection and may not compete favorably with other available options for the treatment of ATTR-CM, including VYNDAQEL/VYNDAMAX, which is marketed by Pfizer and administered in pill form, and ATTRUBY, which is marketed by BridgeBio and administered in pill form, or other available options for the treatment of hATTR-PN in adults, including WAINUA, which is…” |
Quoted from the company's 10-K filed Feb 12, 2026.
Companies that name ALNY in their SEC reports
| Relationship to ALNY | Company | Filing | Sentence |
|---|---|---|---|
| partner | Arbutus Biopharma Corp (ABUS) | 10-K Mar 23, 2026 | “In 2012, we entered into a license agreement with Alnylam that entitles Alnylam to develop and commercialize products with our LNP technology in exchange for milestone and royalty payments.” |
| supplier | VEEVA SYSTEMS INC (VEEV) | 10-K Mar 20, 2026 | “Our life sciences customers range from the largest global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and Idorsia Pharmaceuticals Ltd. We…” |
| partner | Tenaya Therapeutics, Inc. (TNYA) | 10-K Mar 11, 2026 | “our collaboration with Alnylam, including potential targets, research and development strategy, the timing and duration of the collaboration, expected payments, and the achievement of milestones;” |
| partner | Vir Biotechnology, Inc. (VIR) | 10-K Feb 23, 2026 | “Collaboration and License Agreement with Alnylam” |
| partner | Krystal Biotech, Inc. (KRYS) | 10-K Feb 17, 2026 | “•Gene Silencing Approaches: We are aware of two companies, Takeda Pharmaceutical Company Limited (in partnership with Arrowhead Pharmaceutical Inc.) and Novo Nordisk A/S (in partnership with Alnylam Pharmaceuticals, Inc.), which are developing interfering RNA medicines to treat the liver manifestations of AATD.” |
| partner | AGIOS PHARMACEUTICALS, INC. (AGIO) | 10-K Feb 12, 2026 | “•the amount and timing of future milestone and royalty payments potentially payable to Alnylam Pharmaceuticals, Inc. pursuant to the license agreement entered into in July 2023;” |
| partner | REGENERON PHARMACEUTICALS, INC. (REGN) | 10-K Feb 4, 2026 | “See the "Collaboration, License, and Other Agreements" section below for descriptions of our agreements with Alnylam Pharmaceuticals, Inc. and Intellia Therapeutics, Inc.” |
| partner | NOVARTIS AG (NVS) | 20-F Feb 4, 2026 | “Novartis obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, Inc.” |
| partner | ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | 10-K Nov 25, 2025 | “Pursuant to this acquisition, Roche assigned to the Company its entire rights under certain licenses including: the License and Collaboration Agreement between Roche and Alnylam dated July 8, 2007; the Non-Exclusive Patent License Agreement between Roche and MDRNA, Inc. dated February 12, 2009 ("MDRNA License"); and the Non-Exclusive License Agreement between Roche and City of Hope dated September 19, 2011 (collec…” |
ALNY company outlook (results filed Jul 30, 2026)
- “We have lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy.”
Quoted word-for-word from the SEC 8-K results press release.
ALNY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $2.25 | $2.41 | -6.7% | $1.43B | 14 |
| Next quarter (ends Dec 2026) | $2.85 | $2.89 | -1.6% | $1.57B | 13 |
| Current fiscal year (ends Dec 2026) | $8.86 | $9.42 | -5.9% | $5.48B | 14 |
| Next fiscal year (ends Dec 2027) | $12.36 | $13.44 | -8.1% | $6.89B | 13 |
ALNY options: expected move
Options price a move of about ±14.4% (±$32.80) by Nov 20, 2026, which includes earnings on Oct 29, 2026. Over the last 8 reports the stock moved ±9.3% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 63.7% | ±14.4% |
| Dec 18, 2026 | 56 | 57.2% | ±18.1% |
| Jan 15, 2027 | 84 | 55.9% | ±21.6% |
| Mar 19, 2027 | 147 | 56.6% | ±28.7% |
| Jun 17, 2027 | 237 | 55.4% | ±35.5% |
| Sep 17, 2027 | 329 | 54.5% | ±40.9% |
30-day implied volatility 62.5% vs 40.5% realized over the last 30 trading days. Put/call ratio (volume) 1.87. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 15:07 UTC)
| Price | USD 223.24 |
|---|---|
| Change | ▼ 1.78% (down) |
| Previous Close | USD 227.28 |
| Open | USD 227.28 |
| Day Range | USD 222 – 227.28 |
| 52-Week Range | USD 197.81 – 485.36 |
| Volume | 239,900 shares |
| Market Cap | $29.87B |
| Exchange | NMS |
Technical Analysis (ALNY)
Nexqual's technical model rates ALNY "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of October 23, 2026 at 15:07 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 38.41 (neutral) |
| vs SMA50 | Below (USD 239.04) |
| MACD | -4.25 (negative) |
Analyst Ratings (ALNY)
Wall Street analysts rate ALNY "Buy" based on 30 analysts, with a mean price target of USD 368.7 (range USD 250–536), per Nexqual as of October 23, 2026 at 15:07 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 30 |
| Mean Target | USD 368.7 |
| High Target | USD 536 |
| Low Target | USD 250 |
| Buy / Hold / Sell | 23 / 7 / 0 |
Earnings (ALNY)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 2.25 |
| Revenue Estimate | $1.43B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.84 vs est 2.14 ▼ miss |
| 2026-03-31 | USD 1.99 vs est 1.47 ▲ beat |
| 2025-12-31 | USD 1.25 vs est 1.5 ▼ miss |
| 2025-09-30 | USD 2.9 vs est 1.75 ▲ beat |
Source: Nexqual, October 23, 2026 at 15:07 UTC.
Financials & Fundamentals (ALNY)
| Total Revenue | $4.80B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +66.90% |
| Gross Margin | +79.65% |
| Operating Margin | +17.93% |
| Profit Margin | +16.13% |
| ROE | +96.56% |
| Debt / Equity | 2.21 |
| Current Ratio | 3.06 |
| Total Cash | $3.31B |
| Total Debt | $2.99B |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | $465.38M (12.5% of revenue) |
Source: Nexqual, October 23, 2026 at 15:07 UTC.
Financial Health Score (ALNY)
Nexqual rates Alnylam Pharmaceuticals, Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 15:07 UTC.
| Growth | Strong — Revenue +65% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 80%, operating 18% (last 12 months) |
| Balance Sheet | Weak — $3.31B cash and investments vs $1.01B debt (Jun 2026, SEC), net cash |
| Cash Flow | Solid — FCF $465M (FY ended Dec 2025, 10-K), 13% margin |
| Efficiency | Strong — ROE 97%, ROA 12.3% |
Ownership (ALNY)
| Insider Ownership | +0.18% |
|---|---|
| Institutional Ownership | +101.54% |
| Shares Outstanding | 133.81M |
| Float | 133.22M |
| Short % of Float | +7.68% |
Source: Nexqual, October 23, 2026 at 15:07 UTC.
Leadership (ALNY)
Alnylam Pharmaceuticals, Inc. is led by Yvonne L. Greenstreet, CEO & Director, per Nexqual as of October 23, 2026 at 15:07 UTC.
| CEO & Director | Yvonne L. Greenstreet |
|---|---|
| CFO & Executive VP | Jeffrey V. Poulton |
| Executive VP, Chief Scientific Officer and Head of Early Research & Early Development | Kevin Joseph Fitzgerald |
| Vice President of Investor Relations | Joshua Brodsky |
Major Backers & Investors (ALNY)
Notable institutional backers of Alnylam Pharmaceuticals, Inc. include Capital Group, FMR, LLC, Growth Fund of America, according to Nexqual as of October 23, 2026 at 15:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 15.62% |
| FMR, LLC | 11.23% |
| Growth Fund of America | 6.7% |
| T. Rowe Price | 4.22% |
| Amcap Fund | 3.38% |
| Invesco | 2.81% |
| JPMorgan | 2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 9.4% |
| BlackRock | 8.15% |
| State Street | 2.66% |
Source: Nexqual, October 23, 2026 at 15:07 UTC.
From Alnylam Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- In March 2025, the United States Food and Drug Administration, or the FDA, approved our supplemental New Drug Application, or sNDA, for AMVUTTRA for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
- In parallel, we advanced a proprietary technology that conjugates a sugar molecule, referred to as GalNAc, to the siRNA molecule.
- We believe this success will enable us to sustainably and organically create and commercialize transformative medicines that benefit patients around the world across a broad range of disease areas and indications.
- Our platform enhancements have also provided a strong foundation for pursuing a conjugate-based approach to extrahepatic delivery, including delivery to the brain and spinal cord, as well as ocular delivery.
Partnerships
- We also intend to continue to build on our progress with extrahepatic delivery during 2026, advancing our CNS programs under our collaboration with Regeneron, as well as continuing to advance our other extrahepatic delivery initiatives, in support of our Alnylam 2030 goal to expand to ten tissue types by the end of 2030.
- We are also advancing our C16 technology as part of our collaboration with Regeneron, including work on ALN-HTT02, our investigational RNAi therapeutic in development for the treatment of Huntington's disease, or HD, which is a devastating, fatal neurodegenerative disease for which there are currently no approved disease-modifying therapies.
Legal & Regulatory Risks (Item 1A, quoted)
- The marketing and sale of our approved products, including AMVUTTRA for ATTR amyloidosis with cardiomyopathy, or any future products for which we or our collaborators receive regulatory approval may be unsuccessful or less successful than anticipated.
- We or our collaborators may be unable to obtain regulatory approval for our or our collaborated product candidates, and, as a result, we or our collaborators may be unable to commercialize such product candidates.
- We may incur significant liability if enforcement authorities allege or determine that we are engaging in commercial activities with respect to our unapproved product candidates or promoting our commercially approved products in a way that violates applicable regulations.
- Any products we currently market or may develop in the future may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ROIV | Roivant Sciences Ltd. | USD 36.71 | ▼ 1.99% |
| RPRX | Royalty Pharma plc | USD 63.33 | ▼ 0.66% |
| GMAB | Genmab A/S | USD 39.67 | ▼ 0.82% |
| INCY | Incyte Corporation | USD 115.4 | ▼ 1.31% |
| RVMD | Revolution Medicines, Inc. | USD 187.18 | ▼ 0.27% |
| BNTX | BioNTech SE | USD 88.1 | ▼ 1.75% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 15:07 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt